



PRESS RELEASE

For Immediate Release

Corgenix Announces Collaboration with SpectraCell Laboratories

Aspirin effect testing will be added to lab's advanced cardiovascular assessment services

DENVER, Colo. — July 28, 2008 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced its collaboration with SpectraCell Corporation, a Houston, Texas-based specialized clinical testing laboratory company providing cardiovascular and nutritional testing nationwide.

Under terms of the relationship Corgenix' AspirinWorks[®] product will be used to assess aspirin effect as part of SpectraCell's extensive cardiovascular risk assessment services.

"SpectraCell is increasingly recognized as a major lab in the U.S. for individualized cardiovascular testing and risk assessment. Their unique approach to cardiovascular medicine provides a perfect fit for aspirin effect testing," said Douglass Simpson, Corgenix' President and Chief Executive Officer. "This new association, combined with their physician-directed sales force, is an important step for Corgenix, and we look forward to a long-term relationship."

The collaboration will allow SpectraCell to take advantage of Corgenix' unique diagnostic assay that determines the effect of aspirin on platelets in apparently healthy individuals by measuring the level of thromboxane production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. Clinical studies suggest that more than 25 percent of all patients taking aspirin are not sufficiently protected from suffering a cardiovascular event.

"This arrangement further expands our functional testing capabilities to include aspirin effect," said Dr. Fred Crawford, VP of Operations and Technical Director at SpectraCell Laboratories. "Partnering with Corgenix helps insure that SpectraCell continues to deliver the most advanced technology and highest quality service to our physician clients nationwide."

Physicians interested in learning more about SpectraCell's advanced clinical testing may call 800-227-5227 or e-mail info@spectracell.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin non-responsiveness. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently

sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

About SpectraCell Laboratories

SpectraCell is a CLIA accredited laboratory that services healthcare providers nationwide by providing an innovative assessment of a patient's nutritional and cardiovascular status. Unlike traditional serum, hair and urine tests, SpectraCell's patented FIA™ (Functional Intracellular Analysis) measures how an individual's white blood cells respond to varied environments of vitamins, minerals, amino acids and antioxidants. By evaluating the functionality of specific nutrients in a patient's own cells, individual differences in metabolism, age, genetics, health, prescription drug usage, absorption rate or other factors are taken into consideration, opening a true "window on intracellular function." Unlike traditional cholesterol tests, SpectraCell's LPP™ directly measures both the size and number of several classes of lipoprotein particles, including critical risk factors as cited by the National Cholesterol Education Program, giving an accurate assessment of cardiovascular risk.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP and CFO
Phone: 303-453-8903
Email: wcritchfield@corgenix.com

Media Contact:

Dan Snyders
Vice President and Public Relations Supervisor
Armada Medical Marketing
Phone: 303-623-1190 x 230
Fax: 303-623-1191
dan@armadamedical.com